Divi's Laboratories shares in focus as weight loss drug receives EU panel backing

Analysts believe Divi's Laboratories is likely to be the intermediate supplier of orforglipron for weight loss. The stock may see a reaction in today's trading session.
Read the full report on Cnbctv18
Story file
- Section
- Business
- Topics
- Stock market
- First reported by
- Cnbctv18
- Reporter
- shloka badkar
- Published
- Monday, 19 October 2026, 8:08 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Cnbctv18 with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

